BMY Jun 2024 43.000 call
OPR - OPR Delayed price. Currency in USD
Add to watchlist
As of 03:23PM EDT. Market open.
| Previous close | 0.2900 |
| Open | 0.2300 |
| Bid | 0.0000 |
| Ask | 0.0000 |
| Strike | 43.00 |
| Expiry date | 2024-06-21 |
| Day's range | 0.2300 - 0.3400 |
| Contract range | N/A |
| Volume | |
| Open interest | 4.05k |
Business WireKRAZATI (adagrasib) Demonstrated Statistically Significant Improvement in Progression-Free Survival in Patients with Pretreated Locally Advanced or Metastatic KRASG12C-Mutated Non-Small Cell Lung Cancer
PRINCETON, N.J., June 01, 2024--KRAZATI (adagrasib) Demonstrated Statistically Significant Improvement in Progression-Free Survival in Patients with Pretreated Locally Advanced....
ZacksBristol Myers (BMY) Gets EC Nod for Opdivo Label Expansion
Bristol Myers' (BMY) Opdivo combination regimen receives the European Commission's approval for the first-line treatment of unresectable or metastatic urothelial carcinoma.
ZacksBristol Myers Squibb Company (BMY) Is a Trending Stock: Facts to Know Before Betting on It
Bristol Myers (BMY) has received quite a bit of attention from Zacks.com users lately. Therefore, it is wise to be aware of the facts that can impact the stock's prospects.
© 2024 Yahoo. All rights reserved.